DE60327768D1 - Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease - Google Patents
Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-proteaseInfo
- Publication number
- DE60327768D1 DE60327768D1 DE60327768T DE60327768T DE60327768D1 DE 60327768 D1 DE60327768 D1 DE 60327768D1 DE 60327768 T DE60327768 T DE 60327768T DE 60327768 T DE60327768 T DE 60327768T DE 60327768 D1 DE60327768 D1 DE 60327768D1
- Authority
- DE
- Germany
- Prior art keywords
- drug
- hiv
- phenotypic
- mutational profiles
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000869 mutational effect Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 title 1
- 230000002596 correlated effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009510 drug design Methods 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 238000007876 drug discovery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39275302P | 2002-07-01 | 2002-07-01 | |
| PCT/EP2003/050277 WO2004003817A1 (en) | 2002-07-01 | 2003-06-30 | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60327768D1 true DE60327768D1 (de) | 2009-07-09 |
Family
ID=30000930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60327768T Expired - Lifetime DE60327768D1 (de) | 2002-07-01 | 2003-06-30 | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7217506B2 (de) |
| EP (1) | EP1520247B1 (de) |
| AT (1) | ATE432506T1 (de) |
| AU (1) | AU2003254500B2 (de) |
| CA (1) | CA2490862A1 (de) |
| DE (1) | DE60327768D1 (de) |
| WO (1) | WO2004003817A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246859T3 (es) * | 1999-05-28 | 2006-03-01 | Virco Bvba | Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos. |
| EP1356082A2 (de) * | 2000-10-20 | 2003-10-29 | Virco Bvba | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase |
| DE60321466D1 (de) * | 2002-07-01 | 2008-07-17 | Tibotec Pharm Ltd | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase |
| EP1520247B1 (de) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| US20050214744A1 (en) * | 2002-07-01 | 2005-09-29 | Hilde Azjin | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| US7372540B2 (en) * | 2004-10-12 | 2008-05-13 | Asml Netherlands B.V. | Lithographic apparatus and device manufacturing method |
| DK1856125T3 (da) | 2005-02-25 | 2009-12-07 | Tibotec Pharm Ltd | Syntese af proteasehæmmerforstadie |
| CA2609910A1 (en) * | 2005-05-27 | 2006-12-07 | Monogram Biosciences, Inc. | Methods and compositions for determining resistance of hiv-1 to protease inhibitors |
| ES2428563T3 (es) * | 2006-01-19 | 2013-11-08 | Monogram Biosciences, Inc. | Método para determinar la resistencia de VIH a tratamiento con inhibidor de proteasa |
| JP5297814B2 (ja) * | 2006-02-03 | 2013-09-25 | ビルコ・ビーブイビーエイ | 量的ｈｉｖ表現型又は向性アッセイ |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US327742A (en) * | 1885-10-06 | Machine for making nuts | ||
| GB2229340B (en) | 1989-03-17 | 1994-02-09 | Technophone Ltd | Radio telephone system |
| GB8918226D0 (en) | 1989-08-09 | 1989-09-20 | Wellcome Found | Dna assays |
| EP0428000A1 (de) | 1989-11-03 | 1991-05-22 | Abbott Laboratories | Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität |
| US5235039A (en) | 1991-06-10 | 1993-08-10 | Eli Lilly And Company | Substrates for hiv protease |
| AU4248593A (en) | 1992-05-14 | 1993-12-13 | Mark Holodniy | Polymerase chain reaction assays for monitoring antiviral therapy |
| US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
| US5685141A (en) | 1995-12-26 | 1997-11-11 | General Electric Company | Lock for nozzle control in the event of hydraulic failure |
| BR9704637A (pt) | 1996-01-26 | 1998-06-09 | Innogenetics Nv | Processo para deteção de mutações induzidas por droga no gene de transcrição reversa |
| KR100495690B1 (ko) | 1996-01-26 | 2005-11-08 | 비르코 비브이비에이 | 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법 |
| EP0852626B1 (de) | 1996-01-29 | 2002-04-03 | Virologic, Inc. | Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe |
| JP3062459B2 (ja) | 1996-08-14 | 2000-07-10 | 理化学研究所 | ポリエステル重合酵素遺伝子及びポリエステルの製造方法 |
| NZ508834A (en) | 1998-05-26 | 2004-06-25 | Virologic Inc | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy |
| AU4673399A (en) | 1998-05-28 | 1999-12-13 | Visible Genetics Inc. | Use of polymorphisms as a predictor of drug-resistance mutations |
| CA2872424C (en) | 1998-06-23 | 2017-03-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv |
| BR9912209A (pt) | 1998-06-24 | 2002-11-05 | Virologic Inc | Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids |
| AU762811B2 (en) * | 1998-06-24 | 2003-07-03 | Innogenetics N.V. | Method for detection of drug-selected mutations in the HIV protease gene |
| ES2246859T3 (es) | 1999-05-28 | 2006-03-01 | Virco Bvba | Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos. |
| AU5758200A (en) | 1999-06-22 | 2001-01-09 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| AU5883300A (en) | 1999-06-23 | 2001-01-09 | Penn State Research Foundation, The | Compositions and methods for the quantification of sterol biosynthetic flux |
| ATE526423T1 (de) | 2000-04-18 | 2011-10-15 | Virco Bvba | Verfahren zum messen des medikamentenwiderstands gegen hcv |
| AU2001256318B8 (en) | 2000-04-20 | 2007-03-22 | Virco Bvba | Method for mutation detection in HIV using pol sequencing |
| EP1352356B1 (de) | 2000-06-08 | 2009-10-14 | Virco Bvba | Verfahren um die resistenz gegen ein therapeutisches agenz vorherzusagen unter verwendung neuronaler netze |
| US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
| WO2002022076A2 (en) | 2000-09-15 | 2002-03-21 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| EP1356082A2 (de) | 2000-10-20 | 2003-10-29 | Virco Bvba | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase |
| JP4264256B2 (ja) | 2000-10-20 | 2009-05-13 | ビルコ・ビーブイビーエイ | 治療に対する耐性を予測するための生物学的カット−オフ値の確立 |
| JP2002199890A (ja) | 2000-10-23 | 2002-07-16 | Inst Of Physical & Chemical Res | 生分解性ポリエステル合成酵素の改変方法 |
| CA2429073A1 (fr) | 2000-11-10 | 2002-05-16 | Bioalliance Pharma | Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih) |
| US7659404B2 (en) | 2001-02-14 | 2010-02-09 | Tibotec Pharmaceuticals Ltd. | Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors |
| US20050214744A1 (en) | 2002-07-01 | 2005-09-29 | Hilde Azjin | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| EP1520247B1 (de) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| DE60321466D1 (de) | 2002-07-01 | 2008-07-17 | Tibotec Pharm Ltd | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase |
| CA2497979A1 (en) | 2002-09-06 | 2004-03-18 | Elan Pharmaceuticals, Inc. | 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| EP1605064A1 (de) | 2004-06-07 | 2005-12-14 | UMC Utrecht Holding B.V. | HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind. |
-
2003
- 2003-06-30 EP EP03761598A patent/EP1520247B1/de not_active Expired - Lifetime
- 2003-06-30 AT AT03761598T patent/ATE432506T1/de not_active IP Right Cessation
- 2003-06-30 CA CA002490862A patent/CA2490862A1/en not_active Abandoned
- 2003-06-30 WO PCT/EP2003/050277 patent/WO2004003817A1/en not_active Ceased
- 2003-06-30 DE DE60327768T patent/DE60327768D1/de not_active Expired - Lifetime
- 2003-06-30 AU AU2003254500A patent/AU2003254500B2/en not_active Ceased
- 2003-06-30 US US10/519,035 patent/US7217506B2/en not_active Expired - Fee Related
-
2006
- 2006-12-20 US US11/613,584 patent/US8592161B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1520247A1 (de) | 2005-04-06 |
| US8592161B2 (en) | 2013-11-26 |
| AU2003254500A1 (en) | 2004-01-19 |
| US20070269816A1 (en) | 2007-11-22 |
| CA2490862A1 (en) | 2004-01-08 |
| US20050233312A1 (en) | 2005-10-20 |
| US7217506B2 (en) | 2007-05-15 |
| AU2003254500B2 (en) | 2009-11-19 |
| ATE432506T1 (de) | 2009-06-15 |
| EP1520247B1 (de) | 2009-05-27 |
| WO2004003817A1 (en) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1185712B8 (de) | Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz | |
| Hellard et al. | Hepatitis C transmission and treatment as prevention–The role of the injecting network | |
| Lythgoe et al. | Shared SARS-CoV-2 diversity suggests localised transmission of minority variants | |
| DE60327768D1 (de) | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease | |
| ATE343003T1 (de) | Amplifizierung von nukleinsäuresequenzen mittels multiplex priming | |
| GB0130267D0 (en) | Focussed antibody technology | |
| DK2332582T3 (da) | ACE2-aktivering til behandling af hjerte-, lunge-og nyresygdomme samt forhøjet blodtryk | |
| Jabara et al. | Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection | |
| DE60222590D1 (de) | Methoden zur feststellung von akute myeloischen leukämie | |
| WO2004043232A3 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| DE60321466D1 (de) | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase | |
| WO2004038381A3 (en) | Methods for drug discovery, disease treatment, and diagnosis using metabolomics | |
| ATE384263T1 (de) | Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen | |
| MXPA03003476A (es) | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. | |
| WO2003093492A3 (en) | Compositions and methods for determining susceptibility of hepatitis c virus to anti-viral drugs | |
| WO2002022076A3 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids | |
| ATE375400T1 (de) | Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren | |
| EP1407042A4 (de) | Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids | |
| Mertz | CRISPR tech behind super-sensitive, smartphone COVID test | |
| Hoff et al. | Looking for men in all the wrong places…: HIV prevention small-group programs do not reach high risk gay men | |
| Magiorkinis et al. | An innovative study design to assess the community effect of interventions to mitigate HIV epidemics using transmission-chain phylodynamics | |
| AU2014347768A1 (en) | HCV genotyping algorithm | |
| WO2005033280A8 (en) | Hiv-dependent expression constructs and uses therefor | |
| Lasek-Nesselquist et al. | A statewide analysis of SARS-CoV-2 transmission in New York | |
| KR200208239Y1 (ko) | 특정인의 ｄｎａ구조를 형상화한 팔찌 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |